David Badesch
Concepts (509)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 115 | 2025 | 1957 | 6.510 |
Why?
| | Antihypertensive Agents | 33 | 2025 | 519 | 2.780 |
Why?
| | Epoprostenol | 23 | 2015 | 132 | 1.770 |
Why?
| | Recombinant Fusion Proteins | 9 | 2025 | 663 | 1.380 |
Why?
| | Vasodilator Agents | 12 | 2015 | 326 | 1.090 |
Why?
| | Vascular Resistance | 11 | 2025 | 365 | 1.010 |
Why?
| | Registries | 22 | 2025 | 2400 | 0.970 |
Why?
| | Familial Primary Pulmonary Hypertension | 17 | 2024 | 194 | 0.950 |
Why?
| | Pulmonary Wedge Pressure | 9 | 2024 | 66 | 0.900 |
Why?
| | Piperazines | 8 | 2014 | 368 | 0.860 |
Why?
| | Sulfones | 7 | 2012 | 127 | 0.850 |
Why?
| | Exercise Tolerance | 21 | 2025 | 289 | 0.840 |
Why?
| | Hemodynamics | 30 | 2024 | 1114 | 0.820 |
Why?
| | Scleroderma, Systemic | 7 | 2021 | 124 | 0.710 |
Why?
| | Connective Tissue Diseases | 5 | 2018 | 85 | 0.690 |
Why?
| | Practice Guidelines as Topic | 7 | 2020 | 1591 | 0.680 |
Why?
| | Sulfonamides | 13 | 2018 | 594 | 0.660 |
Why?
| | Exercise Test | 12 | 2025 | 637 | 0.660 |
Why?
| | Double-Blind Method | 26 | 2025 | 2070 | 0.650 |
Why?
| | Respiratory System Agents | 2 | 2023 | 22 | 0.610 |
Why?
| | Natriuretic Peptide, Brain | 10 | 2025 | 110 | 0.610 |
Why?
| | Phenylpropionates | 5 | 2011 | 27 | 0.600 |
Why?
| | Pulmonary Artery | 14 | 2023 | 1116 | 0.580 |
Why?
| | Pyridazines | 5 | 2011 | 56 | 0.550 |
Why?
| | Adult | 79 | 2025 | 41087 | 0.530 |
Why?
| | Endothelin Receptor Antagonists | 10 | 2015 | 60 | 0.530 |
Why?
| | Cardiac Catheterization | 13 | 2024 | 571 | 0.530 |
Why?
| | Humans | 146 | 2025 | 146342 | 0.500 |
Why?
| | Middle Aged | 81 | 2025 | 36619 | 0.490 |
Why?
| | Activins | 2 | 2025 | 28 | 0.450 |
Why?
| | Treatment Outcome | 34 | 2025 | 11821 | 0.440 |
Why?
| | Pyrimidines | 4 | 2024 | 532 | 0.430 |
Why?
| | Lung Transplantation | 10 | 2025 | 326 | 0.410 |
Why?
| | Disease Management | 6 | 2016 | 651 | 0.410 |
Why?
| | Male | 93 | 2025 | 73396 | 0.390 |
Why?
| | Female | 90 | 2025 | 79499 | 0.380 |
Why?
| | Aged | 44 | 2025 | 26432 | 0.370 |
Why?
| | Risk Assessment | 14 | 2024 | 3712 | 0.360 |
Why?
| | Consensus | 1 | 2014 | 467 | 0.360 |
Why?
| | Thrombosis | 1 | 2016 | 398 | 0.360 |
Why?
| | Anticoagulants | 3 | 2016 | 746 | 0.340 |
Why?
| | Anemia, Sickle Cell | 5 | 2014 | 324 | 0.340 |
Why?
| | Pyrazoles | 3 | 2024 | 517 | 0.320 |
Why?
| | Prognosis | 16 | 2021 | 4351 | 0.320 |
Why?
| | Thinness | 1 | 2011 | 100 | 0.310 |
Why?
| | Prostaglandins | 3 | 2007 | 94 | 0.310 |
Why?
| | Survival Rate | 15 | 2022 | 2092 | 0.300 |
Why?
| | Blood Pressure | 8 | 2014 | 1765 | 0.290 |
Why?
| | Oxygen Consumption | 1 | 2012 | 721 | 0.290 |
Why?
| | Hypertension, Portal | 4 | 2011 | 66 | 0.280 |
Why?
| | Activities of Daily Living | 3 | 2016 | 442 | 0.280 |
Why?
| | Sildenafil Citrate | 8 | 2014 | 60 | 0.280 |
Why?
| | Follow-Up Studies | 18 | 2025 | 5439 | 0.270 |
Why?
| | Coagulants | 1 | 2008 | 20 | 0.270 |
Why?
| | Factor VIIa | 1 | 2008 | 43 | 0.270 |
Why?
| | Lung Neoplasms | 1 | 2021 | 2675 | 0.260 |
Why?
| | Hospitalization | 9 | 2025 | 2475 | 0.260 |
Why?
| | Purines | 8 | 2014 | 188 | 0.250 |
Why?
| | Depressive Disorder | 1 | 2010 | 361 | 0.250 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 6073 | 0.250 |
Why?
| | Drug Therapy, Combination | 8 | 2025 | 1036 | 0.250 |
Why?
| | Quality of Life | 12 | 2025 | 3200 | 0.250 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 731 | 0.250 |
Why?
| | Mixed Connective Tissue Disease | 2 | 2010 | 10 | 0.250 |
Why?
| | Health Status | 2 | 2016 | 827 | 0.230 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 2 | 2025 | 51 | 0.230 |
Why?
| | Pulmonary Medicine | 3 | 2019 | 78 | 0.220 |
Why?
| | Prospective Studies | 16 | 2021 | 8123 | 0.220 |
Why?
| | Phosphodiesterase 5 Inhibitors | 3 | 2014 | 41 | 0.220 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 928 | 0.210 |
Why?
| | Hemorrhage | 2 | 2008 | 825 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 11 | 2021 | 2022 | 0.200 |
Why?
| | Castleman Disease | 1 | 2003 | 16 | 0.200 |
Why?
| | Walk Test | 4 | 2025 | 82 | 0.190 |
Why?
| | Herpesvirus 8, Human | 1 | 2003 | 67 | 0.190 |
Why?
| | DEAE-Dextran | 1 | 2023 | 1 | 0.190 |
Why?
| | Referral and Consultation | 2 | 2025 | 881 | 0.190 |
Why?
| | United States | 21 | 2025 | 16136 | 0.190 |
Why?
| | Muscle, Smooth, Vascular | 6 | 1994 | 449 | 0.180 |
Why?
| | Phosphodiesterase Inhibitors | 4 | 2009 | 73 | 0.180 |
Why?
| | Peptide Fragments | 5 | 2025 | 693 | 0.180 |
Why?
| | Herpesviridae Infections | 1 | 2003 | 147 | 0.180 |
Why?
| | Adolescent | 22 | 2021 | 22557 | 0.180 |
Why?
| | Disease Progression | 6 | 2025 | 2867 | 0.180 |
Why?
| | Body Mass Index | 1 | 2011 | 2458 | 0.180 |
Why?
| | Ventricular Function, Right | 5 | 2009 | 300 | 0.180 |
Why?
| | Biomarkers | 6 | 2021 | 4340 | 0.170 |
Why?
| | Insulin-Like Growth Factor I | 4 | 1994 | 320 | 0.170 |
Why?
| | Lung | 7 | 2019 | 4122 | 0.160 |
Why?
| | Medication Adherence | 1 | 2025 | 535 | 0.160 |
Why?
| | Fluid Shifts | 1 | 2020 | 2 | 0.160 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 76 | 0.160 |
Why?
| | Severity of Illness Index | 10 | 2024 | 2921 | 0.160 |
Why?
| | Rituximab | 1 | 2021 | 208 | 0.160 |
Why?
| | Kaplan-Meier Estimate | 5 | 2025 | 970 | 0.160 |
Why?
| | Heart | 2 | 2023 | 626 | 0.150 |
Why?
| | Methamphetamine | 1 | 2021 | 75 | 0.150 |
Why?
| | Infusions, Intravenous | 7 | 2009 | 432 | 0.150 |
Why?
| | Vasculitis | 2 | 1998 | 69 | 0.150 |
Why?
| | Exercise Therapy | 1 | 2025 | 488 | 0.150 |
Why?
| | Somatomedins | 2 | 1990 | 28 | 0.150 |
Why?
| | Echocardiography | 4 | 2020 | 645 | 0.150 |
Why?
| | Walking | 8 | 2014 | 546 | 0.150 |
Why?
| | Sodium Chloride | 1 | 2020 | 138 | 0.150 |
Why?
| | Thorax | 1 | 2019 | 51 | 0.140 |
Why?
| | Diagnostic Techniques, Respiratory System | 1 | 2019 | 5 | 0.140 |
Why?
| | Endothelin A Receptor Antagonists | 2 | 2011 | 24 | 0.140 |
Why?
| | HLA-DP alpha-Chains | 1 | 2018 | 4 | 0.140 |
Why?
| | Immunologic Factors | 1 | 2021 | 244 | 0.140 |
Why?
| | Isoxazoles | 3 | 2008 | 57 | 0.140 |
Why?
| | SOXF Transcription Factors | 1 | 2018 | 16 | 0.140 |
Why?
| | Thiophenes | 3 | 2008 | 117 | 0.140 |
Why?
| | Transforming Growth Factor beta | 1 | 2021 | 467 | 0.140 |
Why?
| | HLA-DP beta-Chains | 1 | 2018 | 88 | 0.140 |
Why?
| | Administration, Oral | 9 | 2015 | 872 | 0.130 |
Why?
| | Time Factors | 14 | 2018 | 7109 | 0.130 |
Why?
| | Young Adult | 10 | 2021 | 14330 | 0.130 |
Why?
| | Algorithms | 5 | 2019 | 1849 | 0.130 |
Why?
| | Liver Diseases | 3 | 2011 | 304 | 0.130 |
Why?
| | Blood Coagulation | 2 | 2016 | 267 | 0.130 |
Why?
| | Obesity | 1 | 2011 | 3131 | 0.130 |
Why?
| | Psychometrics | 2 | 2018 | 712 | 0.120 |
Why?
| | Comorbidity | 5 | 2019 | 1665 | 0.120 |
Why?
| | Proportional Hazards Models | 6 | 2022 | 1331 | 0.120 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 340 | 0.120 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2018 | 190 | 0.110 |
Why?
| | B-Lymphocytes | 1 | 2021 | 887 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2024 | 1763 | 0.110 |
Why?
| | Pyridines | 2 | 2015 | 610 | 0.110 |
Why?
| | Iloprost | 2 | 2006 | 45 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2019 | 399 | 0.110 |
Why?
| | Calcium Channel Blockers | 2 | 2024 | 165 | 0.110 |
Why?
| | Pulmonary Edema | 1 | 1995 | 105 | 0.110 |
Why?
| | Tetrazoles | 1 | 2015 | 50 | 0.110 |
Why?
| | Cohort Studies | 7 | 2020 | 6077 | 0.110 |
Why?
| | Graft Rejection | 1 | 1998 | 516 | 0.100 |
Why?
| | Hemolysis | 2 | 2014 | 242 | 0.100 |
Why?
| | Survival Analysis | 8 | 2018 | 1378 | 0.100 |
Why?
| | Models, Theoretical | 2 | 2015 | 561 | 0.100 |
Why?
| | Case-Control Studies | 5 | 2018 | 3647 | 0.100 |
Why?
| | Antibodies, Antinuclear | 1 | 1993 | 60 | 0.100 |
Why?
| | Pilot Projects | 4 | 2010 | 1888 | 0.100 |
Why?
| | Acute Disease | 3 | 2008 | 1038 | 0.100 |
Why?
| | Protein Kinase C | 2 | 1994 | 250 | 0.100 |
Why?
| | Hypothyroidism | 1 | 1993 | 68 | 0.090 |
Why?
| | Societies, Medical | 2 | 2015 | 907 | 0.090 |
Why?
| | Echocardiography, Doppler | 2 | 2014 | 117 | 0.090 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 944 | 0.090 |
Why?
| | Colorado | 3 | 2022 | 4595 | 0.090 |
Why?
| | Respiratory Function Tests | 5 | 2018 | 543 | 0.090 |
Why?
| | Exercise | 4 | 2024 | 2213 | 0.090 |
Why?
| | Delphi Technique | 1 | 2014 | 350 | 0.090 |
Why?
| | Endpoint Determination | 2 | 2010 | 84 | 0.090 |
Why?
| | Incidence | 5 | 2015 | 2936 | 0.090 |
Why?
| | Injections, Subcutaneous | 2 | 2023 | 170 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 516 | 0.090 |
Why?
| | Pulmonary Circulation | 3 | 2018 | 431 | 0.090 |
Why?
| | Survival | 1 | 2011 | 38 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2020 | 1503 | 0.080 |
Why?
| | Peptidyl-Dipeptidase A | 3 | 2003 | 57 | 0.080 |
Why?
| | Risk Factors | 9 | 2018 | 10921 | 0.080 |
Why?
| | Pain | 2 | 2011 | 790 | 0.080 |
Why?
| | United Kingdom | 3 | 2021 | 377 | 0.080 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 1995 | 370 | 0.080 |
Why?
| | Prevalence | 4 | 2010 | 2861 | 0.080 |
Why?
| | Long-Term Care | 1 | 2011 | 118 | 0.080 |
Why?
| | Reference Values | 2 | 2009 | 796 | 0.080 |
Why?
| | Respiration, Artificial | 1 | 1995 | 711 | 0.080 |
Why?
| | Michigan | 1 | 2010 | 203 | 0.080 |
Why?
| | Animals, Newborn | 5 | 1994 | 888 | 0.070 |
Why?
| | Endothelin-1 | 2 | 2002 | 177 | 0.070 |
Why?
| | Retrospective Studies | 8 | 2025 | 17438 | 0.070 |
Why?
| | Pulmonary Alveoli | 2 | 2005 | 385 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2018 | 594 | 0.070 |
Why?
| | Aldosterone | 1 | 2009 | 42 | 0.070 |
Why?
| | Dinoprostone | 1 | 1989 | 179 | 0.070 |
Why?
| | Elastin | 1 | 1989 | 78 | 0.070 |
Why?
| | Vasopressins | 1 | 2009 | 60 | 0.070 |
Why?
| | Pulmonary Eosinophilia | 1 | 1989 | 28 | 0.070 |
Why?
| | Transaminases | 1 | 2008 | 22 | 0.070 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 61 | 0.070 |
Why?
| | Vasoconstrictor Agents | 1 | 2009 | 148 | 0.070 |
Why?
| | Renal Insufficiency | 1 | 2010 | 173 | 0.070 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2011 | 391 | 0.070 |
Why?
| | Maximum Tolerated Dose | 2 | 2025 | 217 | 0.070 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 1989 | 96 | 0.070 |
Why?
| | Aged, 80 and over | 8 | 2021 | 8391 | 0.070 |
Why?
| | Hospitals, University | 1 | 2008 | 178 | 0.070 |
Why?
| | Multivariate Analysis | 4 | 2015 | 1543 | 0.070 |
Why?
| | Lung Diseases | 2 | 2010 | 787 | 0.070 |
Why?
| | Heart Failure | 2 | 2020 | 2329 | 0.060 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2004 | 499 | 0.060 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2009 | 248 | 0.060 |
Why?
| | Airway Obstruction | 1 | 2009 | 152 | 0.060 |
Why?
| | Lupus Erythematosus, Systemic | 3 | 2010 | 241 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 3 | 2018 | 2488 | 0.060 |
Why?
| | Drug Utilization | 1 | 2008 | 171 | 0.060 |
Why?
| | Endothelins | 1 | 2007 | 61 | 0.060 |
Why?
| | Drug Costs | 1 | 2008 | 116 | 0.060 |
Why?
| | Hypophosphatemia | 1 | 2006 | 16 | 0.060 |
Why?
| | Hypokalemia | 1 | 2006 | 23 | 0.060 |
Why?
| | Appetite Depressants | 1 | 2006 | 19 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2009 | 1064 | 0.060 |
Why?
| | Autoimmune Diseases | 2 | 2005 | 467 | 0.060 |
Why?
| | Phosphorus | 1 | 2006 | 89 | 0.060 |
Why?
| | Educational Measurement | 1 | 1989 | 331 | 0.060 |
Why?
| | Potassium | 1 | 2006 | 151 | 0.060 |
Why?
| | Ventricular Function | 1 | 2006 | 53 | 0.060 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2005 | 17 | 0.060 |
Why?
| | Cattle | 5 | 1994 | 940 | 0.060 |
Why?
| | Telangiectasis | 1 | 2025 | 7 | 0.060 |
Why?
| | Epistaxis | 1 | 2025 | 16 | 0.060 |
Why?
| | Medical Informatics | 1 | 2006 | 102 | 0.060 |
Why?
| | CREST Syndrome | 2 | 2002 | 6 | 0.060 |
Why?
| | Pleural Diseases | 1 | 2005 | 23 | 0.060 |
Why?
| | Analysis of Variance | 3 | 2009 | 1298 | 0.060 |
Why?
| | Probability | 3 | 2015 | 309 | 0.060 |
Why?
| | Forecasting | 3 | 2021 | 388 | 0.050 |
Why?
| | Immunohistochemistry | 3 | 2005 | 1712 | 0.050 |
Why?
| | Child | 6 | 2011 | 22693 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2008 | 1361 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2016 | 2113 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2024 | 116 | 0.050 |
Why?
| | Arthritis, Rheumatoid | 3 | 2010 | 1185 | 0.050 |
Why?
| | Carbon Monoxide | 2 | 2018 | 82 | 0.050 |
Why?
| | Heterozygote | 1 | 2025 | 311 | 0.050 |
Why?
| | Physicians, Family | 1 | 2005 | 179 | 0.050 |
Why?
| | Age Distribution | 3 | 2010 | 399 | 0.050 |
Why?
| | Sex Distribution | 3 | 2010 | 382 | 0.050 |
Why?
| | Physician's Role | 1 | 2005 | 225 | 0.050 |
Why?
| | Terminology as Topic | 1 | 2005 | 253 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 693 | 0.050 |
Why?
| | Polymyositis | 1 | 2002 | 13 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2003 | 426 | 0.050 |
Why?
| | Scleroderma, Localized | 1 | 2002 | 11 | 0.050 |
Why?
| | Dermatomyositis | 1 | 2002 | 24 | 0.050 |
Why?
| | Serotonin Antagonists | 1 | 2002 | 33 | 0.050 |
Why?
| | Thromboxane-A Synthase | 1 | 2002 | 3 | 0.050 |
Why?
| | Heart Defects, Congenital | 2 | 2009 | 923 | 0.050 |
Why?
| | Liver Function Tests | 3 | 2011 | 103 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2003 | 1031 | 0.040 |
Why?
| | Enzyme Inhibitors | 2 | 2004 | 823 | 0.040 |
Why?
| | Hypoxia | 3 | 2018 | 1211 | 0.040 |
Why?
| | Drug Administration Schedule | 4 | 2008 | 790 | 0.040 |
Why?
| | Cardiac Surgical Procedures | 1 | 2008 | 611 | 0.040 |
Why?
| | Mutation | 2 | 2025 | 4093 | 0.040 |
Why?
| | Signal Transduction | 4 | 2025 | 5246 | 0.040 |
Why?
| | Animals | 11 | 2013 | 38107 | 0.040 |
Why?
| | Biomarkers, Pharmacological | 1 | 2021 | 26 | 0.040 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 24 | 0.040 |
Why?
| | Tricuspid Valve Insufficiency | 2 | 2011 | 23 | 0.040 |
Why?
| | Cardiovascular Agents | 1 | 2023 | 165 | 0.040 |
Why?
| | Least-Squares Analysis | 1 | 2021 | 73 | 0.040 |
Why?
| | Injections, Intravenous | 2 | 2013 | 197 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2002 | 245 | 0.040 |
Why?
| | Clinical Competence | 1 | 1989 | 1272 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2018 | 2240 | 0.040 |
Why?
| | Multicenter Studies as Topic | 2 | 2006 | 417 | 0.040 |
Why?
| | Tropoelastin | 2 | 1991 | 11 | 0.040 |
Why?
| | Reproductive History | 1 | 2020 | 12 | 0.040 |
Why?
| | Cells, Cultured | 5 | 1994 | 4118 | 0.040 |
Why?
| | Risk | 2 | 2015 | 920 | 0.040 |
Why?
| | Self Report | 1 | 2025 | 870 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2003 | 511 | 0.040 |
Why?
| | Europe | 2 | 2012 | 421 | 0.040 |
Why?
| | Infusion Pumps | 1 | 2000 | 33 | 0.040 |
Why?
| | Jaw | 1 | 2000 | 27 | 0.040 |
Why?
| | Cardiac Output | 1 | 2020 | 176 | 0.040 |
Why?
| | Radiography | 2 | 1995 | 861 | 0.040 |
Why?
| | Genotype | 4 | 2009 | 1879 | 0.040 |
Why?
| | Delivery of Health Care | 1 | 2006 | 947 | 0.040 |
Why?
| | Transplantation, Homologous | 2 | 1998 | 416 | 0.040 |
Why?
| | Autoimmunity | 1 | 2005 | 925 | 0.040 |
Why?
| | Placebos | 2 | 2011 | 192 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3416 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2020 | 138 | 0.040 |
Why?
| | Spinal Diseases | 1 | 1999 | 50 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 1999 | 64 | 0.040 |
Why?
| | Gonadal Steroid Hormones | 1 | 2020 | 143 | 0.040 |
Why?
| | Thrombocytopenia | 1 | 2021 | 206 | 0.040 |
Why?
| | Uric Acid | 1 | 2000 | 167 | 0.030 |
Why?
| | Internship and Residency | 1 | 1989 | 1281 | 0.030 |
Why?
| | Lung Diseases, Interstitial | 1 | 2005 | 677 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2018 | 74 | 0.030 |
Why?
| | Immunosuppressive Agents | 3 | 1998 | 829 | 0.030 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 1999 | 163 | 0.030 |
Why?
| | Methicillin Resistance | 1 | 1998 | 17 | 0.030 |
Why?
| | Plasmapheresis | 1 | 1998 | 24 | 0.030 |
Why?
| | Cell Division | 4 | 1994 | 736 | 0.030 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2018 | 78 | 0.030 |
Why?
| | Hemoptysis | 1 | 1998 | 34 | 0.030 |
Why?
| | Bronchiolitis Obliterans | 1 | 1998 | 59 | 0.030 |
Why?
| | Models, Statistical | 1 | 2022 | 669 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2000 | 220 | 0.030 |
Why?
| | Cervical Vertebrae | 1 | 1999 | 170 | 0.030 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 1998 | 61 | 0.030 |
Why?
| | Disease-Free Survival | 2 | 2010 | 778 | 0.030 |
Why?
| | Fatal Outcome | 1 | 1998 | 302 | 0.030 |
Why?
| | Biomedical Technology | 1 | 2017 | 49 | 0.030 |
Why?
| | Capillaries | 1 | 1998 | 123 | 0.030 |
Why?
| | Child, Preschool | 2 | 2011 | 11913 | 0.030 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1997 | 43 | 0.030 |
Why?
| | Health Status Indicators | 2 | 2009 | 167 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 1997 | 177 | 0.030 |
Why?
| | Faculty, Medical | 2 | 1990 | 309 | 0.030 |
Why?
| | Colonic Diseases | 1 | 1996 | 39 | 0.030 |
Why?
| | Mycoplasma | 1 | 1996 | 5 | 0.030 |
Why?
| | Intestinal Perforation | 1 | 1996 | 46 | 0.030 |
Why?
| | Mycoplasma Infections | 1 | 1996 | 17 | 0.030 |
Why?
| | Desensitization, Immunologic | 1 | 1997 | 91 | 0.030 |
Why?
| | Mass Screening | 2 | 2018 | 1307 | 0.030 |
Why?
| | Translating | 1 | 2016 | 46 | 0.030 |
Why?
| | Cardiomyopathy, Dilated | 1 | 1999 | 357 | 0.030 |
Why?
| | Blood Coagulation Factors | 1 | 1996 | 71 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 1997 | 93 | 0.030 |
Why?
| | Myocardium | 2 | 1998 | 948 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2016 | 171 | 0.030 |
Why?
| | Endothelium, Vascular | 2 | 1994 | 952 | 0.030 |
Why?
| | Pulmonary Emphysema | 1 | 1998 | 276 | 0.030 |
Why?
| | Dyspnea | 2 | 2008 | 251 | 0.030 |
Why?
| | Fibrinolysis | 1 | 1996 | 162 | 0.030 |
Why?
| | Lactobacillus | 1 | 1994 | 28 | 0.030 |
Why?
| | Calibration | 1 | 2015 | 154 | 0.030 |
Why?
| | Recurrence | 1 | 1998 | 1133 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 2 | 1994 | 128 | 0.030 |
Why?
| | Immunization, Passive | 1 | 1994 | 90 | 0.030 |
Why?
| | Drug Approval | 1 | 2015 | 94 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2014 | 3017 | 0.030 |
Why?
| | Antisickling Agents | 1 | 2014 | 8 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 69 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 262 | 0.030 |
Why?
| | Hydroxyurea | 1 | 2014 | 36 | 0.030 |
Why?
| | Immunoglobulins | 1 | 1994 | 162 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 208 | 0.030 |
Why?
| | Social Behavior | 1 | 2016 | 279 | 0.020 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 1994 | 72 | 0.020 |
Why?
| | Thyroiditis | 1 | 1993 | 4 | 0.020 |
Why?
| | Raynaud Disease | 1 | 1993 | 3 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 1998 | 397 | 0.020 |
Why?
| | Research | 2 | 2009 | 421 | 0.020 |
Why?
| | Genetic Variation | 1 | 2018 | 996 | 0.020 |
Why?
| | Cross-Sectional Studies | 3 | 2016 | 5899 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 1994 | 172 | 0.020 |
Why?
| | Pneumonia, Bacterial | 1 | 1994 | 114 | 0.020 |
Why?
| | Administration, Intravenous | 1 | 2014 | 172 | 0.020 |
Why?
| | Immunoenzyme Techniques | 2 | 1994 | 197 | 0.020 |
Why?
| | Focus Groups | 1 | 2016 | 588 | 0.020 |
Why?
| | Enzyme Activation | 2 | 1994 | 759 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2363 | 0.020 |
Why?
| | Erythrocyte Indices | 1 | 2012 | 33 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 419 | 0.020 |
Why?
| | Down Syndrome | 1 | 1999 | 529 | 0.020 |
Why?
| | Cytomegalovirus Infections | 1 | 1994 | 206 | 0.020 |
Why?
| | Creatinine | 1 | 2014 | 511 | 0.020 |
Why?
| | Pulmonary Embolism | 1 | 2015 | 246 | 0.020 |
Why?
| | Embolism, Air | 1 | 1992 | 14 | 0.020 |
Why?
| | Erythrocyte Transfusion | 1 | 2014 | 226 | 0.020 |
Why?
| | Cell-Derived Microparticles | 1 | 2012 | 73 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 1537 | 0.020 |
Why?
| | Chronic Disease | 2 | 2015 | 1827 | 0.020 |
Why?
| | Cardiomegaly | 2 | 2006 | 175 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 197 | 0.020 |
Why?
| | Preoperative Care | 2 | 2009 | 396 | 0.020 |
Why?
| | Biomedical Research | 1 | 2017 | 729 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 559 | 0.020 |
Why?
| | Thromboxane B2 | 1 | 1989 | 23 | 0.020 |
Why?
| | Calcimycin | 1 | 1989 | 36 | 0.020 |
Why?
| | Mortality | 1 | 2012 | 375 | 0.020 |
Why?
| | Nitric Oxide | 1 | 1994 | 883 | 0.020 |
Why?
| | Phenotype | 3 | 2010 | 3206 | 0.020 |
Why?
| | Drug Synergism | 1 | 1990 | 354 | 0.020 |
Why?
| | Mental Health | 1 | 2016 | 779 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 640 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2014 | 478 | 0.020 |
Why?
| | Angiopoietin-1 | 1 | 2009 | 12 | 0.020 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2009 | 23 | 0.020 |
Why?
| | Health Policy | 1 | 2012 | 399 | 0.020 |
Why?
| | Receptors, Retinoic Acid | 1 | 2009 | 44 | 0.020 |
Why?
| | Health Care Costs | 1 | 2012 | 423 | 0.020 |
Why?
| | Aromatase | 1 | 2009 | 37 | 0.020 |
Why?
| | Spironolactone | 1 | 2009 | 40 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1989 | 175 | 0.020 |
Why?
| | Fellowships and Scholarships | 2 | 1990 | 355 | 0.020 |
Why?
| | Dyspepsia | 1 | 2008 | 11 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1990 | 1041 | 0.020 |
Why?
| | California | 1 | 2010 | 475 | 0.020 |
Why?
| | Hepatitis, Autoimmune | 1 | 2008 | 11 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 1989 | 110 | 0.020 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2009 | 69 | 0.020 |
Why?
| | Qualitative Research | 1 | 2016 | 1734 | 0.020 |
Why?
| | Vital Capacity | 1 | 2009 | 293 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2009 | 329 | 0.020 |
Why?
| | Vibrio Infections | 1 | 1987 | 2 | 0.020 |
Why?
| | Echocardiography, Transesophageal | 1 | 2009 | 132 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 614 | 0.020 |
Why?
| | Cystic Fibrosis | 1 | 1998 | 1164 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 451 | 0.020 |
Why?
| | Cognition | 1 | 2016 | 1292 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2009 | 221 | 0.020 |
Why?
| | Headache | 1 | 2008 | 150 | 0.020 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 154 | 0.020 |
Why?
| | American Heart Association | 1 | 2009 | 364 | 0.020 |
Why?
| | Endocarditis, Bacterial | 1 | 1987 | 46 | 0.020 |
Why?
| | Aminorex | 1 | 2006 | 2 | 0.020 |
Why?
| | Heart Rate | 1 | 2010 | 846 | 0.010 |
Why?
| | RNA, Messenger | 2 | 1997 | 2791 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 1989 | 449 | 0.010 |
Why?
| | Odds Ratio | 1 | 2009 | 1077 | 0.010 |
Why?
| | Alleles | 1 | 2009 | 907 | 0.010 |
Why?
| | Hypoventilation | 1 | 1985 | 17 | 0.010 |
Why?
| | Hepatitis C | 1 | 2008 | 251 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2006 | 279 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2005 | 183 | 0.010 |
Why?
| | Estradiol | 1 | 2009 | 517 | 0.010 |
Why?
| | Gene Expression Regulation | 2 | 1997 | 2599 | 0.010 |
Why?
| | Magnesium | 1 | 1985 | 155 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 3 | 2006 | 3926 | 0.010 |
Why?
| | Pancreatic Elastase | 1 | 2004 | 54 | 0.010 |
Why?
| | Hypotension | 1 | 1985 | 125 | 0.010 |
Why?
| | Drug Prescriptions | 1 | 2006 | 314 | 0.010 |
Why?
| | Fibroblasts | 1 | 1989 | 1034 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1998 | 0.010 |
Why?
| | DNA | 1 | 1990 | 1421 | 0.010 |
Why?
| | Logistic Models | 1 | 2009 | 2126 | 0.010 |
Why?
| | Potassium Channels | 1 | 2004 | 149 | 0.010 |
Why?
| | Tablets | 1 | 2003 | 41 | 0.010 |
Why?
| | Aging | 1 | 1994 | 1996 | 0.010 |
Why?
| | Critical Care | 1 | 1989 | 706 | 0.010 |
Why?
| | Research Design | 1 | 2009 | 1143 | 0.010 |
Why?
| | Arginine | 1 | 2004 | 264 | 0.010 |
Why?
| | Angiotensin II | 1 | 2003 | 102 | 0.010 |
Why?
| | Sex Factors | 1 | 2008 | 2107 | 0.010 |
Why?
| | Liver Transplantation | 1 | 2009 | 751 | 0.010 |
Why?
| | Rats | 2 | 2004 | 5586 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2010 | 1219 | 0.010 |
Why?
| | Sepsis | 1 | 1987 | 669 | 0.010 |
Why?
| | Heart Ventricles | 1 | 2006 | 762 | 0.010 |
Why?
| | Practice Patterns, Physicians' | 1 | 2010 | 1408 | 0.010 |
Why?
| | Colorimetry | 1 | 2000 | 12 | 0.010 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 449 | 0.010 |
Why?
| | Spinal Osteophytosis | 1 | 1999 | 3 | 0.010 |
Why?
| | Spinal Cord Compression | 1 | 1999 | 24 | 0.010 |
Why?
| | Spinal Stenosis | 1 | 1999 | 31 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 604 | 0.010 |
Why?
| | Veins | 1 | 1999 | 68 | 0.010 |
Why?
| | Heart Atria | 1 | 2000 | 139 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1999 | 317 | 0.010 |
Why?
| | Calcium-Transporting ATPases | 1 | 1997 | 33 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 1997 | 54 | 0.010 |
Why?
| | Arteries | 1 | 1999 | 261 | 0.010 |
Why?
| | Heart-Lung Transplantation | 1 | 1997 | 12 | 0.010 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1997 | 58 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 334 | 0.010 |
Why?
| | Liver Cirrhosis | 1 | 1999 | 278 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1761 | 0.010 |
Why?
| | Blotting, Western | 1 | 1999 | 1177 | 0.010 |
Why?
| | Spinal Cord | 1 | 1999 | 378 | 0.010 |
Why?
| | Systole | 1 | 1997 | 179 | 0.010 |
Why?
| | Diverticulitis, Colonic | 1 | 1996 | 11 | 0.010 |
Why?
| | von Willebrand Factor | 1 | 1996 | 84 | 0.010 |
Why?
| | Respiration | 1 | 1996 | 208 | 0.010 |
Why?
| | Proteins | 2 | 1992 | 1022 | 0.010 |
Why?
| | Physical Fitness | 1 | 1997 | 209 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 1999 | 541 | 0.010 |
Why?
| | Cilazapril | 1 | 1995 | 1 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1995 | 26 | 0.010 |
Why?
| | Thymidine | 1 | 1994 | 57 | 0.010 |
Why?
| | Ganciclovir | 1 | 1994 | 51 | 0.010 |
Why?
| | Subcellular Fractions | 1 | 1994 | 73 | 0.010 |
Why?
| | Opportunistic Infections | 1 | 1994 | 47 | 0.010 |
Why?
| | Lung Diseases, Obstructive | 1 | 1994 | 43 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1999 | 778 | 0.010 |
Why?
| | Acyclovir | 1 | 1994 | 97 | 0.010 |
Why?
| | Blood | 1 | 1994 | 107 | 0.010 |
Why?
| | Tissue Donors | 1 | 1997 | 425 | 0.010 |
Why?
| | Vimentin | 1 | 1994 | 47 | 0.010 |
Why?
| | Immunoglobulins, Intravenous | 1 | 1994 | 134 | 0.010 |
Why?
| | Viremia | 1 | 1994 | 158 | 0.010 |
Why?
| | Gene Expression | 1 | 1998 | 1463 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1864 | 0.010 |
Why?
| | Factor VIII | 1 | 1994 | 107 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1994 | 567 | 0.010 |
Why?
| | Immunocompromised Host | 1 | 1994 | 201 | 0.010 |
Why?
| | Sputum | 1 | 1994 | 302 | 0.010 |
Why?
| | Neovascularization, Pathologic | 1 | 1994 | 287 | 0.010 |
Why?
| | Lymph | 1 | 1992 | 31 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1991 | 197 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1994 | 1163 | 0.000 |
Why?
| | Extracellular Matrix Proteins | 1 | 1991 | 156 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1994 | 689 | 0.000 |
Why?
| | Financing, Government | 1 | 1990 | 53 | 0.000 |
Why?
| | Research Support as Topic | 1 | 1990 | 83 | 0.000 |
Why?
| | Career Mobility | 1 | 1990 | 68 | 0.000 |
Why?
| | National Institutes of Health (U.S.) | 1 | 1990 | 147 | 0.000 |
Why?
| | Pneumonia, Viral | 1 | 1994 | 387 | 0.000 |
Why?
| | Rats, Sprague-Dawley | 1 | 1995 | 2537 | 0.000 |
Why?
| | Sheep | 1 | 1992 | 870 | 0.000 |
Why?
| | Tomography, X-Ray Computed | 1 | 1999 | 2786 | 0.000 |
Why?
| | Vibrio | 1 | 1987 | 4 | 0.000 |
Why?
| | Hepatitis, Alcoholic | 1 | 1987 | 18 | 0.000 |
Why?
| | Citrates | 1 | 1985 | 41 | 0.000 |
Why?
| | Protein Binding | 1 | 1992 | 2244 | 0.000 |
Why?
| | Kidney Function Tests | 1 | 1985 | 156 | 0.000 |
Why?
| | RNA | 1 | 1991 | 926 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1997 | 3034 | 0.000 |
Why?
| | Disease Models, Animal | 1 | 1995 | 4580 | 0.000 |
Why?
| | Anti-Bacterial Agents | 1 | 1994 | 1942 | 0.000 |
Why?
| | HIV Infections | 1 | 1999 | 3215 | 0.000 |
Why?
| | Infant | 1 | 1994 | 10114 | 0.000 |
Why?
|
|
Badesch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|